
BIA welcomes appointment of UK MEP
pharmafile | October 12, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â BIA, Glenis WillmottÂ
The BioIndustry Association (BIA) has said it welcomes the appointment of UK MEP Glenis Willmott as the rapporteur for the European Parliament on the proposed Clinical Trials Regulation.
Steve Bates, BIA chief executive, said: “Glenis understand the concerns of the UK life science sector and has a strong track record of supporting medical research that can lead to life saving treatments. She understands how the existing rules have played a part in the number of clinical trials in Europe falling over recent years. So, I am delighted that she will be steering this crucial piece of legislation through the European Parliament.
“The proposed Regulation will save time, money and paperwork for companies wishing to run clinical trials across Europe, thus making it easier to develop innovative medicines for patients. Making Europe a globally attractive place to do clinical trials is essential to sustaining and creating high value life science jobs.”
Related Content

What the life sciences industry wants from the next UK government
The stakes are high as the UK general election draws ever closer, and the industry …

BioIndustry Association calls for governmental support ahead of UK general election
In the run-up to the UK’s general election in June, government spending within the life …

Overcoming barriers in rare diseases
In recent months the focus on the need to develop new drugs and fund new …






